Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury

Critical Care Medicine

Volumn 38, Issue 3, 2010, Pages 903-909

  Mersmann, Jan ^a,b   Berkels, Reinhard ^b   Zacharowski, Paula ^b   Tran, Nguyen ^a   Koch, Alexander ^a   Iekushi, Kazuma ^a   Dimmeler, Stefanie ^a   Granja, Tiago F ^a   Boehm, Olaf ^c   Claycomb, William C ^d   Zacharowski, Kai ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CXCL1; Leukocytes; Myocardial ischemia; Preconditioning; Reperfusion; Toll like receptor 2

Indexed keywords

2,3 BIS(PALMITOYLOXY)PROPYL N PALMITOYLCYSTEINYLSERYLLYSINE HYDROXIDE TRIHYDROCHLORIDE; CXCL1 CHEMOKINE; CYCLOHEXIMIDE; DACTINOMYCIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REPERFUSION INJURY; TREATMENT RESPONSE;

EID: 77249096344     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181ce50e6     Document Type: Article

References (45)

1. Uematsu S, Akira S: Toll-like receptors and innate immunity. J Mol Med 2006; 84: 712-725
2. Schaefer L, Babelova A, Kiss E, et al: The matrix component biglycan is proinflamma-tory and signals through toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115:2223-2233
3. Chong AJ, Shimamoto A, Hampton CR, et al: Toll-like receptor 4 mediates ischemia/ reperfusion injury of the heart. J Thorac Car-diovasc Surg 2004; 128:170-179
4. Favre J, Musette P, Douin-Echinard V, et al: Toll-like receptors 2-deficient mice are protected against postischemic coronary endo-thelial dysfunction. Arterioscler Thromb Vasc Biol 2007; 27:1064-1071
5. Oyama J, Blais C Jr, Liu X, et al: Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109:784-789
6. Brown JM, Grosso MA, Terada LS, et al: En-dotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 1989; 86: 2516-2520
7. Smith RM, Lecour S, Sack MN: Innate immunity and cardiac preconditioning: A putative intrinsic cardioprotective program. Car-diovasc Res 2002; 55:474-482
8. Zacharowski K, Otto M, Hafner G, et al: En-dotoxin induces a second window of protection in the rat heart as determined by using p-nitro-blue tetrazolium staining, cardiac troponin T release, and histology. Arterio-scler Thromb Vasc Biol 1999; 19:2276-2280
9. Zacharowski K, Frank S, Otto M, et al: Lipo-teichoic acid induces delayed protection in the rat heart: A comparison with endotoxin. Arterioscler Thromb Vasc Biol 2000; 20: 1521-1528
10. Zacharowski K, Chatterjee PK, Thiemermann C: Delayed preconditioning induced by lipoteichoic acid from B. subtilis and S. au-reus is not blocked by administration of 5-hydroxydecanoate. Shock 2002; 17:19-22
11. Hua F, Ma J, Ha T, et al: Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 2008; 199:75-82
12. Kawai T, Akira S: Toll-like receptor downstream signaling. Arthritis Res Ther 2005; 7:12-19
13. Frevert CW, Huang S, Danaee H, et al: Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation. J Immunol 1995; 154:335-344
14. von Aulock S, Morath S, Hareng L, et al: Lipoteichoic acid from Staphylococcus au-reus is a potent stimulus for neutrophil recruitment. Immunobiology 2003; 208: 413-422
15. Lotz S, Aga E, Wilde I, et al: Highly purified lipoteichoic acid activates neutrophil granu-locytes and delays their spontaneous apopto-sis via CD14 and TLR2. J Leukoc Biol 2004; 75:467-477
16. Sabroe I, Jones EC, Whyte MKB, et al: Regulation of human neutrophil chemokine receptor expression and function by activation of Toll-like receptors 2 and 4. Immunology 2005; 115:90-98
17. Bozic CR, Gerard NP, Uexkull-Guldenband C, et al: The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J Biol Chem 1994; 269:29355-29358
18. Bozic CR, Kolakowski LF Jr, Gerard NP, et al: Expression and biologic characterization of the murine chemokine KC. J Immunol 1995; 154:6048-6057
19. Powers MR, Davies MH, Eubanks JP: Increased expression of chemokine KC, an in-terleukin-8 homologue, in a model of oxygen-induced retinopathy. Curr Eye Res 2005; 30:299-307
20. Chandrasekar B, Smith JB, Freeman GL: Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neutrophil infiltration via lipopolysaccha-ride-induced CXC chemokine. Circulation 2001; 103:2296-2302
21. Frangogiannis NG: The role of the chemo-kines in myocardial ischemia and reperfu-sion. Curr Vasc Pharmacol 2004; 2:163-174
22. Hua HT, Al Badawi H, Entabi F, et al: CXC chemokine expression and synthesis in skeletal muscle during ischemia/reperfusion. J Vasc Surg 2005; 42:337-343
23. Maheshwari A, Christensen RD, Calhoun DA, et al: Circulating CXC-chemokine concentrations in a murine intestinal ischemia-reperfusion model. Fetal Pediatr Pathol 2004; 23:145-157
24. Molls RR, Savransky V, Liu M, et al: Kerati-nocyte-derived chemokine is an early bi-omarker of ischemic acute kidney injury. Am J Physiol Renal Physiol 2006; 290: F1187-F1193
25. De Filippo K, Henderson RB, Laschinger M, et al: Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. J Immunol 2008; 180:4308-4315
26. Boyd JH, Divangahi M, Yahiaoui L, et al: Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-{kappa}B and calcineurin. Infect Immun 2006; 74:6829-6838
27. Claycomb WC, Lanson NA Jr, Stallworth BS, et al: HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998; 95:2979-2984
28. Zacharowski K, Zacharowski PA, Koch A, et al: Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Natl Acad Sci USA 2006; 103:6392-6397
29. Mersmann J, Zacharowski PA, Schmitz I, et al: Caspase inhibitor zVAD.fmk reduces in-farct size after myocardial ischaemia and reperfusion in rats but not in mice. Resuscitation 2008; 79:468-474
30. Mersmann J, Tran N, Zacharowski PA, et al: Rosiglitazone is cardioprotective in a murine model of myocardial I/R. Shock 2008; 30: 64-68
31. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al: The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005; 11:298-304
32. White SM, Constantin PE, Claycomb WC: Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004; 286:H823-H829
33. Applequist SE, Wallin RP, Ljunggren HG: Variable expression of toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol 2002; 14:1065-1074
34. Cristofaro P, Opal SM: Role of toll-like receptors in infection and immunity: Clinical implications. Drugs 2006; 66:15-29
35. Meng X, Ao L, Brown JM, et al: LPS induces late cardiac functional protection against ischemia independent of cardiac and circulating TNF-alpha. Am J Physiol 1997; 273: H1894-H1902
36. Rowland RT, Meng X, Cleveland JC Jr, et al: LPS-induced delayed myocardial adaptation enhances acute preconditioning to optimize postischemic cardiac function. Am J Physiol 1997; 272:H2708-H2715
37. Gao JJ, Xue Q, Zuvanich EG, et al: Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun 2001; 69:751-757
38. Frangogiannis NG, Entman ML: Chemokines in myocardial ischemia. Trends Cardiovasc Med 2005; 15:163-169
39. Stefanovic L, Brenner DA, Stefanovic B: Direct hepatotoxic effect of KC chemokine in the liver without infiltration of neutrophils. Exp Biol Med (Maywood) 2005; 230:573-586
40. Feng G, Ohmori Y, Chang PL: Production of chemokine CXCL1/KC by okadaic acid through the nuclear factor-kappaB pathway. Carcinogenesis 2006; 27:43-52
41. Getting SJ, Di Filippo C, Christian HC, et al: MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct. J Leukoc Biol 2004; 76:845-853
42. Miura M, Fu X, Zhang QW, et al: Neutralization of Gro{alpha} and macrophage inflammatory protein-2 attenuates renal ischemia/ reperfusion injury. Am J Pathol 2001; 159: 2137-2145
43. Tarzami ST, Miao W, Mani K, et al: Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: Recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003; 108:2387-2392
44. Boyd JH, Mathur S, Wang Y, et al: Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-{kappa}B dependent inflammatory response. Cardiovasc Res 2006; 72:384-393
45. Lefer DJ: Do neutrophils contribute to myo-cardial reperfusion injury? Basic Res Cardiol 2002; 97:263-267